Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimagrumab Alone or With Semaglutide in Overweight or Obese Adults
NCT05616013Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of bimagrumab in obesity, sponsored by Eli Lilly and Company. Started Nov 2022; status: completed.
02
Drugs
bimagrumab
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05616013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05616013.